Daily Stock Analysis, CASI, CASI Pharmaceuticals Inc, priceseries

CASI Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.42
Close
3.51
High
3.53
Low
3.36
Previous Close
3.42
Daily Price Gain
0.09
YTD High
4.19
YTD High Date
Jan 7, 2019
YTD Low
3.23
YTD Low Date
Jan 29, 2019
YTD Price Change
-0.44
YTD Gain
-11.14%
52 Week High
8.89
52 Week High Date
Aug 13, 2018
52 Week Low
2.73
52 Week Low Date
Oct 26, 2018
52 Week Price Change
-0.34
52 Week Gain
-8.83%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2017
1.34
Mar 8. 2017
1.44
12 Trading Days
7.77%
Link
LONG
Sep 13. 2017
1.05
Oct 3. 2017
1.75
14 Trading Days
66.80%
Link
LONG
Nov 17. 2017
2.60
Dec 6. 2017
3.40
12 Trading Days
30.78%
Link
LONG
Jan 5. 2018
3.40
Jan 24. 2018
3.92
12 Trading Days
15.23%
Link
LONG
Mar 29. 2018
4.17
Apr 25. 2018
6.65
18 Trading Days
59.48%
Link
LONG
May 1. 2018
7.14
May 16. 2018
7.56
11 Trading Days
5.94%
Link
LONG
Jun 22. 2018
6.28
Jul 10. 2018
7.23
11 Trading Days
15.07%
Link
LONG
Nov 15. 2018
3.52
Dec 6. 2018
3.90
13 Trading Days
10.92%
Link
Company Information
Stock Symbol
CASI
Exchange
NasdaqCM
Company URL
http://www.casipharmaceuticals.com
Company Phone
240-864-2600
CEO
Ken Keyong Ren
Headquarters
Maryland
Business Address
9620 MEDICAL CENTER DR, STE 300, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000895051
About

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. The drugs are Captisol-Enabled, ZEVALIN and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.

Description

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The company's late-stage clinical drug candidates include , such as MARQIBO, a microtubule inhibitor for the treatment of adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular b-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.